Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

Trump unveils deal to expand coverage and lower costs on obesity drugs

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy

The Independent UK

Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits

At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial.

Benzinga

This is the exercise you need to combat obesity and diabetes, new study says

It’s estimated that more than 5.8 million people in the UK are living with diabetes, which is an all-time high, according to Diabetes UK

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk Q3 2025 Earnings Call Transcript

Novo Nordisk A/S (NASDAQ:NVO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. NVO is having a challenging session. See if it is worth your attention here. This transcript is brought to you by Benzinga APIs. For real-time access to our entire…

Benzinga

Novo Nordisk cuts sales and profits guidance amid obesity drug competition

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ever’.

Evening Standard

Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera

Pfizer and Novo Nordisk are in a heated battle to acquire obesity drug developer Metsera, driving legal and market tension.

International Business Times

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion (74.98 billion Danish kroner), slightly below the consensus of $11.88 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

New food warnings could save thousands of peoples’ lives, experts say

Many countries have brought in a mandatory nutritional warning label law

The Independent UK

More than 100,000 obesity deaths ‘could be prevented with new food warnings’

Mandatory nutrient warning labels could deliver substantial health benefits for the population, experts said.

Evening Standard

Trump team is negotiating with weight-loss drug makers to lower prices to $149 a month: report

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that purpose

The Independent UK

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House

Eli Lilly and Company (NYSE:LLY) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.

Benzinga

Child obesity crisis: London has worst record in weight surge for primary school youngsters, report reveals

More than a fifth of Year Six pupils in the capital are obese, according to new study

Evening Standard

Mapped: The areas where almost one in three children are obese

The figures were called ‘extremely concerning’ by the NHS national clinical director for children and young people

The Independent UK

Obesity levels among Reception and Year 6 children in England, by local area

The figures have been published as part of the Government’s National Child Measurement Programme.

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks

Pfizer sues Metsera and Novo Nordisk to block a rival bid in a high-stakes obesity drug merger.

Benzinga

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

Benzinga

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

The Independent UK

Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs

The Independent UK

Scientists discover five new genes which increase obesity risk

Scientists have identified 13 genes that could increase a person’s risk of developing obesity

The Independent UK

The US obesity rate is declining thanks to weight loss drugs, survey finds

There are now 7.6 million fewer American adults living with obesity

MarketBeat

Viking Therapeutics: High Risk, High Reward Play

Viking Therapeutics stock surges as Phase 3 trials progress for its GLP-1 obesity drug, with analysts seeing major upside potential

AAP

Gender lens needed to examine weight management

Weight management for women can be impacted by a variety of biological and emotional factors, with experts saying a gender-focused approach is needed.

Benzinga

Ventyx Stock Is Rallying Thursday: What's Driving The Surge?

Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for VTX3232 in patients with obesity and cardiovascular risk factors.

Benzinga

Why Ventyx (VTYX) Shares Soared 86.5% After Hours?

Ventyx Biosciences Inc. (NASDAQ:VTYX) jumped 86.53% to $7.20 in after-hours trading on Wednesday after the company reported positive Phase 2 trial results for its obesity and cardiovascular risk drug candidate, VTX3232.

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.